KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Deferred Taxes (2019 - 2025)

AbbVie (ABBV) has disclosed Deferred Taxes for 7 consecutive years, with -$385.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Deferred Taxes rose 49.8% to -$385.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$492.0 million, a 66.05% increase, with the full-year FY2025 number at -$492.0 million, up 66.05% from a year prior.
  • Deferred Taxes was -$385.0 million for Q4 2025 at AbbVie, down from $193.0 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $193.0 million in Q3 2025 to a low of -$1.4 billion in Q4 2023.
  • A 5-year average of -$383.0 million and a median of -$322.5 million in 2023 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: crashed 1726.47% in 2022, then surged 169.68% in 2025.
  • AbbVie's Deferred Taxes stood at -$745.0 million in 2021, then skyrocketed by 30.74% to -$516.0 million in 2022, then crashed by 169.57% to -$1.4 billion in 2023, then surged by 44.86% to -$767.0 million in 2024, then skyrocketed by 49.8% to -$385.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Deferred Taxes are -$385.0 million (Q4 2025), $193.0 million (Q3 2025), and -$272.0 million (Q2 2025).